The fact that both HDAC inhibitors (increasing levels of acetylated proteins) and HAT inhibitors (decreasing levels of acetylated proteins) are being pursued as potential drugs to treat thyroid cancer reflects the complexity of the mechanisms involved in the regulation of the acetylation and deacetylation of histones and other proteins in thyroid cancer. This evidence concerns the gene HDAC9 and thyroid gland carcinoma.